BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

REMARKS

Claims 13-23, 25, 27-31, 41, 42, 45 and 53-58 were pending in the subject application. Claim 19 was withdrawn from consideration. By this Amendment, applicants have amended claims 13, 17 and 58. Accordingly, upon entry of this Amendment, claims 13, 17 and 58, as amended, and claims 14-16, 18, 20-23, 25, 27-31, 41, 42, 45 and 53-57 will be pending and under examination.

Applicants maintain that the amendments to claims 13, 17 and 58 do not raise any issue of new matter. Support for amended claim 13 may be found inter alia in the specification, as originally filed, at page 48, line 9 through page 54, line 14. Support for amended claim 17 may be found inter alia in the specification, as originally filed, at page 48, lines 15-21. Support for amended claim 58 may be found inter alia in the specification, as originally filed, at page 112, line 21 through page 114, line 8.

IMPROPER MARKUSH GROUPING

On page 3 of the Office Action, the Examiner rejected claims 13-15, 20-23, 25, 27-31, 41, 42 and 45 as being drawn to an improper Markush group. The Examiner alleged that the recited compounds, while possessing a common utility, differ widely in structure and are not art-recognized equivalents and are thus, independently distinct for the reasons set forth in the restriction requirement. The Examiner specifically alleged that the Markush group represented by the term R3 has variably different definitions,

rendering the claims clearly improper.

In response, but without conceding the correctness of the Examiner's position, applicants have amended claim 13 to limit the definition of R3 to the following structure:



Applicants maintain that as to claim 13 so amended, this ground of rejection is no longer applicable and request this ground of rejection be reconsidered and withdraw.

REJECTION UNDER 35 U.S.C. §112

On page 4 of the Office Action, the Examiner rejected claims 13-18, 20-23, 25, 27-31, 41, 42 and 45 as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), a the time the application was filed, had possession of the claimed invention. The Examiner alleged that the amendment to the definition of B where the moiety may be $-CH_2OCH_3$ is not described in the specification for the genus.

In response, in order to advance the prosecution of the subject application but without conceding the correctness of the Examiner's

position, applicants have amended claim 13 to delete the moiety -CH_2OCH_3 from the definition of B. Applicants maintain that as to claim 13 so amended and claims 14-18, 20-23, 25, 27-31, 41, 42 and 45 which depend therefrom, this ground of rejection is no longer applicable and request this ground of rejection be reconsidered and withdraw.

The Examiner further rejected claims 13-17, 20-23, 25, 27-31, 41, 42 and 45 as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Specifically the Examiner insisted that amendment to the definition of R_2 to include the moiety $-CH_2X(CH_2)N_4$, is not described in the specification. Similarly, the Examiner asserted that the amendments to the definitions of R_5 and R_7 whereby R_5 and R_7 each independently may be -H; F; Cl; Br; I; $-CO_2CH_3$; -CN; $-NO_2$; straight chained or branched C_1-C_7 alkyl, aminoalkyl, carboxamidoalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl, C_3-C_7 cycloalkyl or cycloalkenyl; wherein the alkyl, aminoalkyl, carboxamidoalkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl may be substituted with one or more aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with -F; -Cl; -Br; -I; $-NO_2$; -CN; C_1-C_3 alkyl or carboxamidoalkyl are not described in the specification.

In response, in order to advance the prosecution of the subject application but without conceding the correctness of the Examiner's position, applicants have amended 13 to delete the moiety -$CH_2X(CH_2)N_4$, from the definition of R2 and have deleted the moieties -H; F; Cl; Br; I; -CO_2CH_3; -CN; -NO_2; straight chained or branched C_1-C_7 alkyl, aminoalkyl, carboxamidoalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl, C_3-C_7 cycloalkyl or cycloalkenyl; wherein the alkyl, aminoalkyl, carboxamidoalkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl may be substituted with one or more aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with -F; -Cl; -Br; -I; -NO_2; -CN; C_1-C_3 alkyl and carboxamidoalkyl from the definitions of R5 and R7. Applicants maintain that as to claim 13 so amended and claims 14-17, 20-23, 25, 27-31, 41, 42 and 45 which depend therefrom, this ground of rejection is no longer applicable and request that it be reconsidered and withdrawn.

The Examiner further rejected claim 58 as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The Examiner alleged that the species of claim 58 is not described in the specification.

In response, in order to advance the prosecution of the application but without conceding the correctness of the Examiner's position, applicants have amended claim 58 to correct the structure of the

compound. Applicants maintain that the subject matter of claim 58, as amended, was described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The synthesis of the compound of claim 58 is described in the specification, as originally filed, on page 112, line 21 through page 114, line 8. Accordingly, applicants respectively request that the Examiner reconsider and withdraw this ground of rejection.

The Examiner further rejected claims 13-18, 20-23, 25, 27-31, 41, 42, 45 and 53-58 as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Examiner provided the following reasons:

1. Claims 13-17, 20-23, 25, 27-31, 41, 42 and 45 are vague and indefinite in that it is not known what is meant by the moiety -$CH_2X(CH_2)N_4$.

In response, in order to advance the prosecution of the application but without conceding the correctness of the Examiner's position, applicants have amended claim 13 to delete the moiety -$CH_2X(CH_2)N_4$. Applicants maintain that as to claim 13 so amended, and claims 16-17, 20-23, 25, 27-31, 41, 42 and 45 which depend therefrom, this ground of rejection is no longer applicable and request that it be reconsidered and withdrawn.

2. Claim 17 recites the limitation "R1-C(=O)" in structure. The Examiner alleged that there is insufficient antecedent basis for this limitation in the claim.

In response, in order to advance the prosecution of the application, applicants have amended claim 17 to recite but without conceding the correctness of the Examiner's position "R4-C(=O)" in structure. Applicants maintain that this phrase expressly provides the necessary antecedent basis in claim 13 for claim 17 is. Accordingly, applicants respectively request that the Examiner reconsider and withdraw this ground of rejection.

REJECTIONS UNDER 35 U.S.C. §102

The Examiner rejected claims 13-15, 20-23, 25 and 27 under 35 U.S.C. §102(e) as being anticipated by Atwal, et al., U.S. Patent No. 5,202,330. The Examiner alleged that Atwal teaches the compounds of the instant invention where instant R1 is C(=O)-O-$CH(CH_3)_2$, R_2 is methyl, R3 is C(=O)-O-(CH2)2-4-benzylpiperzaine, B is OH and A is 2-chloro-3-nitrophenyl or 2,3-difluorophenyl and directed applicants' attention to example 34, in column 37 and example 103 in column 89.

In response, but without conceding the correctness of the Examiner's position, applicants have amended claim 13 to remove the moiety -OH from the definition of B. Applicants maintain that Atwal, et al., U.S. Patent No. 5,202,330 does not anticipate the

subject matter of claim 13 so amended. Accordingly, applicants respectfully request as to claim 13 so amended, and claims 14-15, 20-23, 25 and 27 which depend therefrom, the Examiner reconsider and withdrawn this ground of rejection.

The Examiner rejected claims 13, 20-23, 25 and 27 under 35 U.S.C. §102(b) as being anticipated by JP 62-84574, asserting that JP 62-84574 teaches the compounds of the instant invention where instant R1 is C(=O)-O-CH2CH3, R2 is methyl, R3 is C(=O)-O-(CH2)2-pkperizine-CH(phenyl)2, B is OH and A is 3-nitrophenyl.

In response, but without conceding the correctness of the Examiner's position, applicants have amended claim 13 to remove the moiety -OH from the definition of B. Applicants maintain that JP 62-84574 does not anticipate the subject matter of claim 13 so amended. Accordingly, applicants respectfully request as to claim 13 as amended, and claims 14-15, 20-23, 25 and 27 which depend therefrom, the Examiner reconsider and withdrawn this ground of rejection.

The Examiner rejected claims 13, 20-23, 25 and 27 under 35 U.S.C. §102(b) as being anticipated by Nagaranthnam et al., U.S. Patent No. 5,942,517 asserting Nagarathnam teaches the compounds of the instant invention where instant B is OH, and pointing to examples 1-23.

In response, but without conceding the correctness of the

Examiner's position, applicants have amended claim 13 to remove the moiety -OH from the definition of B. Applicants maintain that Nagaranthnam et al., U.S. Patent No. 5,942,517 does not anticipate the subject matter of claim 13 so amended. Accordingly, applicants respectfully request as to claim 13 so amended, and claims 14-15, 20-23, 25 and 27 which depend therefrom, that the Examiner reconsider and withdrawn this ground of rejection.

REJECTION UNDER 35 U.S.C. §103

The Examiner rejected claims 13, 20-23, 25 and 27 under 35 U.S.C. §103(a) as being unpatentble over Atwal et al., U.S. Patent No. 5,202,330. The Examiner alleged that the generic structure of Atwal encompasses the instantly claimed compounds (Formula I, column 3) as claimed herein. The Examiner directed applicants' attention to examples 33, 39, 40, 48, 49, 50, 52, etc. differ only in the nature of the Y substituent. Column 3 defines Y as R11 or -O-R1 where R11 is -A1-NR5R6, etc. and R1 is -A1-NR5R6, etc. Compounds of the instant invention are generically embraced by Atwal in view of the interchangeability of the Y substitutent of the pyrimidine ring system. Thus, according to the Examiner, one of ordinary skill in the art at the time the invention was made would have been motivated to select for example morpholine as well as other possibilities from the generically disclosed alternatives of the reference and in so doing obtain the instant compounds in view of the equivalency teachings outlined above.

In response, but without conceding the correctness of the

Examiner's position, applicants have amended claim 13 to exclude the moieties -OH and $-OCH_3$ from the definition of B. Applicants maintain that Atwal et al., U.S. Patent No. 5,202,330 does not suggest or render obvious the subject matter of claim 13 so amended or the claim dependent therefrom. Accordingly, applicants respectively request that the Examiner reconsider and withdraw this ground of rejection.

DOUBLE PATENTENING REJECTION

The Examiner rejected claims 13-17, 20-23, 25, 27-31, 41, 42, 45, 55, 56 and 58 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-11 and 19-29 of U.S. Patent No. 5,942,517. The Examiner alleged that although the conflicting claims are not identical, they are not patentably distinct from each other because the compounds of U.S. '517 embraces the compounds of the instant invention where B is OH.

The Examiner further rejected claims 13-17, 20-23, 25, 27-31, 41, 42, 45, 55, 56 and 58 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 4-11 of U.S. Patent No. 6,248,747. The Examiner alleged that although the conflicting claims are not identical, they are not patentably distinct from each other because the compounds of U.S. '747 embraces the compounds of the instant invention where B is OH.

The Examiner rejected claims 13-17, 20-23, 25, 27-31, 41, 42, 45, 55, 56 and 58 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 17 of U.S. Patent No. 6,268,369. The Examiner alleged that although the conflicting claims are not identical, they are not patentably distinct from each other because the compounds of U.S. '369 embraces the compounds of the instant invention where B is OH.

The Examiner further rejected claims 13-17, 20-23, 25, 27-31, 41, 42, 45, 55, 56 and 58 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 17 of U.S. Patent No. 6,245,773. The Examiner alleged that although the conflicting claims are not identical, they are not patentably distinct from each other because the compounds of U.S. '773 embraces the compounds of the instant invention where B is OH.

In response, but without conceding the correctness of the Examiner's position, applicants have amended claim 13 to exclude the moiety -OH from the definition of B. Applicants maintain that as to amended claim 13, and claims 14-17, 20-23, 25, 27-31, 41, 42, 45, 55, 56 and 58 which depend therefrom, this ground of rejection is no longer applicable and request that it be reconsidered and withdrawn.

In summary, in light of the remarks and amendments made hereinabove, applicants respectfully request that the Examiner reconsider and withdraw the various grounds of rejection and

objection set forth in the August 12, 2002 Office Action and earnestly solicit allowance of the claims now pending in the subject application, namely, claims 13, 17 and 58, as amended, and claims 14-16, 18, 20-23, 25, 27-31, 41, 42, 45 and 53-57.

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. §1.97(c)(2) and §1.17(p) to supplement the Information Disclosure Statements filed on December 6, 2001, August 14, 2001 and May 15, 2001.

According to 37 C.F.R. §1.97(c), an Information Disclosure Statement shall be considered by the U.S. Patent and Trademark Office if filed before the mailing date of a Final Office Action under C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or other Office Actions which close prosecution in the application, provided that the Statement is accompanied by either (1) the statement specified in 37 C.F.R. §1.97(e) or (2) the fee as set forth in C.F.R. §1.17(p). The fee as set forth in C.F.R. §1.17(p) is $180.00 (ONE-HUNDRED EIGHTY DOLLARS) and a check for this amount is enclosed.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the disclosure which is listed on the attached Form PTO-1449 (**Exhibit 1**), and attached hereto as **Exhibit 2:**

1. U.S. Serial No.: 09/730,458, filed December 5, 2000, Nagarathnam, et al. (**Exhibit 2**)

If a telephone conference would be of assistance in advancing prosecution of the subject application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the enclosed fee of $645.00 ($465.00 for a Three-Month Extension of Time and $180.00 for a Third Supplemental Information Disclosure Statement), is deemed necessary in connection with the filing of this Amendment. However, if a fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Ave of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.



2/12/03

John P. White — Date
Reg. No. 28,678

Marked-up Version of Amendments

Additions to the text are indicated by underlining; deletions are indicated by square brackets.

--13. (Twice Amended) A compound having the structure:



or

;

wherein A is



,



,



,



,



,



,

or



;

wherein each of Y_1, Y_2, Y_3, Y_4 and Y_5 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, -

$OCOR_4$, $-COR_4$, $-CONHR_4$, $-CON(R_4)_2$, or $-COOR_4$; or any two of Y_1, Y_2, Y_3, Y_4 and Y_5 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein X is S; O; or NR_4;

wherein B is -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; alkoxy or thioalkyl; straight chained or branched C_2-C_7 alkenyl; $-SCH_2C_6H_4OR_4$, [$-CH_2OCH_3$,] $-(CH_2)_nC_6H_5$, $-CH_2X(CH_2)_nNHR_4$; $-(CH_2)_nNHR_4$; or $-OR_4$;

with the proviso that B cannot be -OH or $-CH_3$;

wherein R_1 is -H; $-NO_2$; -CN; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; $-N(R_4)_2$; $-OR_4$; $-(CH_2)_pOR_4$; $-COR_4$; $-CO_2R_4$; or $-CON(R_4)_2$;

wherein R_2 is -H; straight chained or branched C_1-C_7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C_3-C_{10} cycloalkyl-C_1-C_{10}-alkyl, C_3-C_{10} cycloalkyl-C_1-C_{10}-monofluoroalkyl or C_3-C_{10} cycloalkyl-C_1-C_{10}-polyfluoroalkyl; -CN; $-CH_2XR_4$, $-CH_2X(CH_2)_pNHR_4$, -

$(CH_2)_nNHR_4$, $-CH_2X(CH_2)_pN(R_4)_2$, $[-CH_2X(CH_2)_pN_4,]$ or $-CH_2X(CH_2)_pNHCXR_7$; or $-OR_4$;

wherein each p is independently an integer from 1 to 7;

wherein each n is independently an integer from 0 to 5;

wherein R_3 is







wherein Z is C_2 -C_7 alkenyl or alkynyl; CH_2; O; CO; CO_2; $CONR_3$; S; SO; SO_2; or NR_4;

wherein Z' is $(CH_2)_o$, CO, $(CH_2)_oCO$, or $CO(CH_2)_o$;

wherein each D is independently CH_2; O; S; NR_4; CO; or CS;

wherein W is C=O; $C=NOR_4$; substituted or unsubstituted phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrolyl, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl or benzimidazolyl, wherein the phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrolyl, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl or benzimidazolyl is substituted with -H, -F, -Cl, -Br, -I, $-NO_2$, -CN, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl,

straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_3-C_7 cycloalkyl, C_3-C_7 monofluorocycloalkyl, C_3-C_7 polyfluorocycloalkyl, C_3-C_7 cycloalkenyl, $-N(R_4)_2$, $-OR_4$, $-COR_4$, $-CO_2R_4$, or $-CON(R_4)_2$;

wherein each V is independently O; S; CH_2; CR_5R_7; $C(R_7)_2$; or NR_7;

wherein each m is independently an integer from 0 to 3;

wherein o is an integer from 1 to 3;

wherein each R is independently -H; -F; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; $-N(R_4)_2$; $-NO_2$; -CN; $-CO_2R_4$; or $-OR_4$;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;

wherein R_5 is aryl or heteroaryl_substituted with one or more F; Cl; Br; I; COR_4; CO_2R_4; $-CON(R_4)_2$; CN; $-NO_2$; $-N(R_4)_2$; $-OR_4$; $-SR_4$; $(CH_2)_oOR_4$; $(CH_2)_oSR_4$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C_2-C_7 alkenyl, C_2-C_7 alkynyl; C_3-C_7 cycloalkyl,

monofluorocycloalkyl, polyfluorocycloalkyl, or cycloalkenyl;

wherein each R_6 is independently -H; straight chained or branched C_1-C_7 alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; or $-OR_4$;

wherein R_7 is aryl or heteroaryl substituted with one or more F; Cl; Br; I; COR_4; CO_2R_4; $-CON(R_4)_2$; CN; $-NO_2$; $-N(R_4)_2$; $-OR_4$; $-SR_4$; $(CH_2)_oOR_4$; $(CH_2)_oSR_4$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C_2-C_7 alkenyl, C_2-C_7 alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl, or cycloalkenyl;

wherein R_8 is -H; substituted or unsubstituted benzyl, benzoyl, phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrolyl, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl, benzimidazolyl or 2-keto-1-benzimidazolinyl, wherein the benzyl, benzoyl, phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrolyl, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl, benzimidazolyl or 2-keto-1-benzimidazolinyl is substituted with -H, -F, -Cl, -Br, -I, $-NO_2$, -CN, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight

chained or branched C_2-C_7 alkynyl, C_3-C_7 cycloalkyl, C_3-C_7 monofluorocycloalkyl, C_3-C_7 polyfluorocycloalkyl, C_3-C_7 cycloalkenyl, $-N(R_4)_2$, $-OR_4$, $-COR_4$, $-CO_2R_4$, or $-CON(R_4)_2$; substituted or unsubstituted straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; substituted or unsubstituted straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or cycloalkenyl, wherein the alkyl, monofluoroalkyl, polyfluoroalkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl is substituted with -H, phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrolyl, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl, benzimidazolyl, $-N(R_3)_2$, $-NO_2$, -CN, $-CO_2R_4$, $-OR_4$;



or a pharmaceutically acceptable salt thereof.--

--17. (Twice Amended) The compound of claim 16 having the structure:



.--